Pyxis Oncology (PYXS) Enterprise Value (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Enterprise Value of -$66.9 million for Q4 2025, up 47.33% year-over-year from -$45.4 million in Q4 2024, and up 12.33% quarter-over-quarter from -$76.3 million in Q3 2025.
Pyxis Oncology (PYXS) Enterprise Value (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Enterprise Value for 6 consecutive years, with -$66.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Enterprise Value rose 47.33% year-over-year to -$66.9 million; the TTM figure through Dec 2025 stood at -$66.9 million (up 47.33% YoY), while the FY2025 annual figure was -$66.9 million, up 47.33% from the prior year.
- Enterprise Value rose to -$66.9 million in Q4 2025 per PYXS's latest filing, from -$76.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$12.2 million in Q2 2025 and bottomed at -$276.2 million in Q4 2021.
- Historically, Enterprise Value has averaged -$118.9 million across 5 years, with a median of -$129.9 million in 2023.
- Annual changes were most pronounced in 2021 — Enterprise Value plunged 1086.88% — and 2023, when it surged 87.83%.
- Pyxis Oncology's Enterprise Value stood at -$276.2 million in 2021, then soared by 34.55% to -$180.8 million in 2022, then jumped by 34.0% to -$119.3 million in 2023, then fell by 6.4% to -$126.9 million in 2024, then soared by 47.33% to -$66.9 million in 2025.
- Business Quant data shows PYXS's Enterprise Value at -$66.9 million in Q4 2025, -$76.3 million in Q3 2025, and -$12.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 2.12 Bn |
| 10 | Pyxis Oncology | 200.93 Mn | 167.94 Mn | - | -33.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.00 Mn |
| Dec 31, 2025 | -66.86 Mn |
| Sep 30, 2025 | -76.26 Mn |
| Jun 30, 2025 | -12.21 Mn |
| Mar 31, 2025 | -14.23 Mn |
| Dec 31, 2024 | -126.93 Mn |
| Sep 30, 2024 | -144.82 Mn |
| Jun 30, 2024 | -26.55 Mn |
| Mar 31, 2024 | -29.44 Mn |
| Dec 31, 2023 | -119.30 Mn |
| Sep 30, 2023 | -132.97 Mn |
| Jun 30, 2023 | -27.37 Mn |
| Mar 31, 2023 | -54.53 Mn |
| Dec 31, 2022 | -180.77 Mn |
| Sep 30, 2022 | -200.01 Mn |
| Jun 30, 2022 | -224.83 Mn |
| Mar 31, 2022 | -248.56 Mn |
| Dec 31, 2021 | -276.21 Mn |
| Sep 30, 2021 | -133.48 Mn |
| Jun 30, 2021 | -142.47 Mn |